Rayner Strengthens Commitment to US Market with Expansion of Memphis Headquarters
Posted on 9/03/2026
Rayner today announced the expansion of its United States headquarters with the opening of a new 10,000 sq. ft. facility in Memphis, Tennessee, reinforcing the company’s commitment to the US as a central pillar of its global growth strategy.
Memphis has served as Rayner’s US base for six years and remains a strategically positioned national logistics hub. The new site, which has recently received its license from the Tennessee Board of Pharmacy, significantly enhances Rayner’s commercial, distribution and service infrastructure nationwide. Over 4,000 sq. ft. of the facility is dedicated warehouse space, strengthening logistics capabilities and supporting the company’s continued growth across its expanding cataract portfolio.
The investment comes at a time of strong momentum for Rayner in the US, marked by the FDA approval of RayOne EMV Toric, the launch of the Sophi Phacoemulsification system and the acquisition of US distribution rights to Anikavisc OVD. The new facility provides the operational foundation to support these advancements, accelerate future launches and maintain high levels of responsiveness and reliability.
In addition to expanded distribution capacity, the site includes a dedicated wet lab designed to support surgeon training as well as future service and repair capabilities for Sophi. The facility houses colleagues across IT, supply chain, customer services, HR, regulatory affairs (RA), quality assurance (QA) and commercial functions, creating an integrated operational hub to better serve US surgeons and partners.
“This expansion underscores the importance of the United States within Rayner’s global strategy,” said Scott Corning, Vice President, Americas at Rayner. “By investing in our Memphis headquarters, we are strengthening our ability to support customers with greater agility, enhanced training resources and a robust distribution network. As our presence continues to grow here, we have the infrastructure in place to be a dependable long-term partner to US surgeons and surgical centers.”
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has had the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2026 Rayner Group, all rights reserved. ‘Rayner’ ‘RayOne’ ‘EMV’ and ‘Sophi’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. Rayner, The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539 | EC 2026-18 EN